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Abstract: Background: Beta-thalassemias are blood disorders characterized by poorly understood
clinical phenotypes ranging from asymptomatic to severe anemia. Metabolic composition of the human
placenta could be affected by the presence of pathological states such as β-thalassemia. The aim of our
study was to describe metabolic changes in chorionic villi samples of fetuses affected by β-thalassemia
compared to a control group by applying a metabolomics approach. Methods: Chorionic villi samples
were differentiated according to the genetic diagnosis of β-thalassemia: control (Group 1, n = 27);
heterozygous (Group 2, n= 7); homozygous (Group 3, n= 7). Gas chromatography–mass spectrometry
was used to detect the metabolic composition of the samples. Subsequently, multivariate and
univariate statistical analysis was performed. The discriminant metabolites were used to identify
the altered pathways. Results: Supervised multivariate models were devised to compare the
groups. The model resulting from the comparison between Group 1 and Group 3 was the most
significant. Discriminant metabolites were identified, and the most altered pathways were as follows:
pentose phosphate pathway (PPP), arachidonic acid metabolism, glycolysis, and gluconeogenesis,
suggesting the presence of an energetic shift toward the PPP and the presence of oxidative stress in
β-thalassemia chorionic villi samples. Conclusions: The metabolomics approach identified a specific
metabolic fingerprint in chorionic villi of fetuses affected by β-thalassemia.
Keywords: β-thalassemia; chorionic villi samples; metabolomics; gas chromatography–mass
spectrometry; pentose phosphate pathway; arachidonic acid metabolism
1. Introduction
β-thalassemias are a group of hereditary blood disorders characterized by abnormal beta globin
production [1]. These conditions result in a broad range of phenotypes, from severe anemia to clinically
asymptomatic forms, and the mechanisms underlying the phenotypic heterogeneity of β-thalassemia
are still poorly understood [2,3]. A better molecular understanding of thalassemias, the development
of procedures for their detection by DNA analysis, and the introduction of chorionic villi sampling and
preimplantation genetic diagnosis (PGD) have improved prenatal detection of these disorders [4,5].
During human placenta development, alterations in metabolite composition could be affected
by the presence of pathological states. The metabolic profile of the placenta may improve our
understanding of abnormal mechanisms such as β-thalassemia and could potentially allow for early
phenotype prediction.
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Metabolomics is one of the most powerful and promising tools for the analysis of placental
metabolism [6–8]. Analytical techniques such as mass spectrometry (MS) can provide information
about tissue metabolites including lipids, amino acids, and high-energy metabolites, thus providing an
efficient method for monitoring altered pathways [9]. This could provide an integrated “snapshot” of
the metabolic change during different conditions [10–12]. Several studies have been performed on the
metabolic alterations in patients with β–thalassemia [13–15]; however, to our knowledge, the metabolic
profile from chorionic villi of β-thalassemia fetuses collected after transabdominal chorionic villi
sampling (TA-CVS) has not yet been evaluated.
The aim of our study was to characterize the metabolic changes in chorionic villi samples of
fetuses affected by β-thalassemia compared to a control group.
2. Materials and Methods
Samples for this prospective study were collected from the Department of Obstetrics and
Gynecology, Prenatal and Preimplantation Genetic Diagnosis, Fetal Therapy, Microcitemico Pediatric
Hospital “A.Cao” in Cagliari, Sardinia, Italy. All women with fetuses at risk ofβ-thalassemia underwent
non-directive genetic counseling and prenatal invasive diagnosis by TA-CVS [16]. After institutional
review board approval, written consent was obtained from all participating women prior to performing
TA-CVS. All chorionic villi sampling (CVS) procedures were performed between the 11th and the
14th weeks of pregnancy by free-hand transabdominal technique by a single operator (G.M.) [17].
After sampling, an adequate specimen of chorionic villi was used for cytogenetic examination, and the
remaining aliquot was reserved for metabolomics analysis. It was frozen within 2 min in liquid
nitrogen and kept at -80 ◦C.
Patient demographics (ethnic group and maternal age), ultrasound data (crown rump length (CRL)
and fetal nuchal translucency (NT) measurement), and biochemical parameters (pregnancy-associated
plasma protein A and free β-human chorionic gonadotropin) were collected in our database (Table 1).
Table 1. Data of the patients enrolled in the study. (Average maternal age, gestational age, nuchal
translucency, and crown-rump length).
Patients (n) Age (years) GestationalAge (weeks) NT (mm) CRL (mm)
Control 27 36.8 ± 5.3 12.72 ± 0.75 2.07 ± 0.9 61.34 ± 9.8
Heterozygotes 7 31.2 ± 4.1 12.2 ± 1.8 1.4 ± 0.4 53.0 ± 5.4
Homozygotes 6 34.7 ± 2.9 11.9 ± 0.55 1.5 ± 0.3 52.9 ± 5.2
n: number of Patients; nuchal translucency (NT); crown-rump length (CRL); data are mean ± standard deviation.
Samples were divided into three groups based on the outcome of the genetic results: normal fetuses
(Group 1, n = 27), heterozygous fetuses (Group 2, n = 7), and homozygous fetuses (Group 3, n = 7).
The metabolomics profiles of Group 1, Group 2, and Group 3 are described in Table 1. The metabolic
profiles of Group 2 and Group 3 were compared to Group 1. In the analyzed cohort, heterozygous and
homozygous fetuses were characterized by the β cd39 (C > T) mutation.
2.1. Sample Preparation
CVS aliquots were analyzed as previously described [18]. The aliquots were mixed with 800 µL of
methanol and 200 µL of Milli-Q water and then vortexed. After 30 min of sonication, samples were
kept at -20 ◦C for 20 min and then centrifuged at 8600 g for 10 min at 4 ◦C. The supernatant was
collected for analysis.
2.2. Gas Chromatography Mass–Spectrometry Analysis and Data Processing
For gas chromatography–mass spectrometry (GC–MS) analysis, 400 µL of each extract was
dried with a vacuum concentrator overnight (Eppendorf concentrator plus, Eppendorf AG,
Hamburg, Germany) and derivatized with 25 µL of methoxyamine dissolved in pyridine
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(10 mg/mL) (Sigma-Aldrich, St. Louis, MO, USA) at 70 ◦C. After 1 h, 50 µL of
N-Methyl-N-(trimethylsilyl)-trifluoroacetamide (MSTFA, Sigma-Aldrich, St. Louis, MO, USA) was
added, and the samples were left at room temperature for 1 h. Successively, samples were diluted
in 50 µL of hexane (Sigma-Aldrich, St. Louis, MO, USA), and 1 µL of derivatized sample was
injected splitless into a 7890A gas chromatograph coupled with a 5975C Network mass spectrometer
(Agilent Technologies, Santa Clara, CA, USA) equipped with a 30 m × 0.25 mm internal diameter
ID fused silica capillary column with a 0.25 µM TG-5MS stationary phase (Thermo Fisher Scientific,
Waltham, MA, USA). The injector and transfer line temperatures were at 250 ◦C and 280 ◦C, respectively.
The gas flow rate through the column was 1 mL/min. The column’s initial temperature was kept
at 60 ◦C for 3 min, increased to 140 ◦C at 7 ◦C/min, held at 140 ◦C for 4 min, increased to 300 ◦C at
5 ◦C/min, and kept for 1 min. The identification of metabolites was performed using the standard
NIST 08 and Golm Metabolome Database (GMD) mass spectra libraries, as well as by comparison with
authentic standards, when available.
The R library XCMS [19,20] was used for peak detection and retention time correction.
Parameters utilized for peak deconvolution for GC–MS matrices were manually optimized.
The resulting matrices were processed using an in-house Python script to eliminate signals present in
the blanks, keeping only the most abundant feature per molecule and modifying all zeros present in
the matrix by inserting half of the minimum value found for a feature. After manual correction of the
filtered matrix to eliminate the internal standard and any possible remaining noise signal, median fold
change normalization was performed using an in-house Python script in order to compensate for
sample dilution biases [21].
2.3. Statistical Analysis
A multivariate statistical analysis was performed on GC–MS data by using SIMCA-P software
(ver. 15.0, Umetrics, Sweden) [22]. The variables were unit variance (UV) scaled. The initial data
analyses were conducted using principal component analysis (PCA), which is important for the
exploration of sample distributions without classification. To identify potential outliers, DmodX and
Hotelling’s T2 tests were applied, and then, a supervised analysis was used. Partial least square
discriminant analysis (PLS-DA) maximizes the discrimination between samples assigned to different
classes. The variance and predictive ability (R2X, R2Y, Q2) were established to evaluate the suitability of
the models. A permutation test (n = 400) was performed to validate the models. The scores from each
PLS-DA model were subjected to a CV-ANOVA (p value < 0.05 was considered statistically significant).
The most significant variables were extracted by the loadings plot from the PLS-DA model.
GraphPad Prism software (version 7.01, GraphPad Software, Inc., San Diego, CA, USA) was used to
perform the univariate statistical analysis of the data resulting from the multivariate analysis. To verify
the significance of the resulting metabolites, a Mann–Whitney U test was performed.
2.4. Pathways Analysis
Metabolic pathways were generated by using MetaboAnalyst 3.0, a web server designed to
obtain comprehensive metabolomic data analysis, visualization, and interpretation [23]. This approach
permits correlation of metabolite changes with metabolic networks. The pathway analysis module of
Metaboanalyst 3.0 combines results from pathway enrichment analysis with the pathway topology
analysis to identify the most relevant pathways involved in the conditions under study. It uses
high-quality KEGG metabolic pathways (Kyoto Encyclopedia of Genes and Genomes) as the backend
knowledge base.
3. Results
Groups 1 (control), 2 (heterozygous), and 3 (homozygous) were compared through multivariate
statistical analysis to highlight possible differences in their metabolic profiles. PCA models for all of
the groups were constructed. One sample from Group 3 was identified as a strong outlier through
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the Hotelling T2 test and was excluded. Furthermore, a PLS-DA model with all three groups was
created (Figure 1A). To identify specific features for each group, models were constructed comparing
the single groups pairwise. The comparison between Group 1 and Group 2 (Figure 1C) was statistically
significant (p-value < 0.05), as was the comparison between Group 1 and Group 3 (Figure 1D), while the
comparison between Group 2 and Group 3 was not significant (Figure 1D). The models were validated
with the respective permutation tests.
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All the statistical parameters of the models are reported in Table 2.
Table 2. Summary of the statistical parameters of the multivariate models.
Supervised Models
N R2X R2Y Q2 p-Value
Permutation Test:
Intercept R2\Q2
C vs. Hom vs. Het 39 0.351 0.484 0.159 ns 0.27/−0.14
Het vs. Hom 13 0.515 0.699 0.246 ns 0.73/−0.03
C vs. Het 34 0.352 0.689 0.390 0.003 0.44/−0.21
C vs. Hom 33 0.486 0.917 0.658 <0.0001 0.55/−0.33
C= control patients; Het = heterozygous for β-thalassemia patients; Hom = homozygous for β-thalassemia patients;
N, number of samples; R2X, R2Y, values indicating the variance of the model; Q2, value indicating the predictive
ability of the model. The p-value was considered significant for values <0.05.
Through analysis of the single models, it was possible to identify the metabolic fingerprint of
each class. The most important metabolites were evaluated through analysis of the loadings plot.
The resulting metabolites from the comparison between the groups underwent univariate analysis by
using the Mann–Whitney U test to evaluate the p-value. Trends of the average concentrations of the
most altered metabolites are reported as b x pl ts in Figure 2.
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Figure 2. Box plots of the most altered metabolites resulting from the comparison between classes 1, 2,
and 3. The average concentrations of the indicated metabolites underwent the Mann–Whitney U test.
(* indicates a p-value < 0.05, ** indicates a p-value < 0.001, *** indicates a p-value < 0.0001).
Glutamic acid, glycerol-1-phosphate, malic acid, arachidonic acid (ARA), glucose, and ribose
were found to significantly increase in homozygous patients, while docosatetranoic acid and
palmitoleic acid were found to decrease when compared with the heterozygous and the control group.
Subsequently, pathway analysis was performed by using the web-based analytical tool Metaboanalyst
4.0. The pathways most altered in homozygous patients were as follows: pentose phosphate pathway
(PPP), ARA metabolism, glutamine and glutamate metabolism, alanine, aspartate and glutamate
metabolism, glycolysis, and gluconeogenesis (Figure 3).
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4. Discussion
New innovative omics technologies offer the possibility to screen for novel biomarkers and to better
understand pathological processes [15,24]. Metabolomics is a tool that can be used with this aim to
investigate common and disabling genetic conditions such as β-thalassemia. Pathological and
environmental stress conditions can change the expression levels of certain genes and, hence,
the metabolite concentrations of the corresponding pathways. The phenotypic and genetic heterogeneity
of β-thalassemia are challenging to study, especially in early gestation. In this study, the metabolome of
chorionic villi was investigated to better understand the still unclear pathophysiological mechanisms
of β-thalassemia. GC–MS analysis and multivariate statistics identified different metabolic profiles
in the chorionic villi of fetuses affected by homozygous compared to heterozygous β-thalassemia
and control fetuses. Glutamic acid, glycerol-1-phosphate, malic acid, ARA, glucose, and ribose were
found to significantly increase in homozygous patients, while docosatetranoic acid and palmitoleic
acid were found to decrease. PPP, ARA metabolism, glutamine and glutamate metabolism, alanine,
aspartate and glutamate metabolism, glycolysis, and gluconeogenesis were potentially altered in both
the homozygous and heterozygous groups.
PPP has two major functions: (1) Production of reduced nicotinamide adenine dinucleotide
phosphate (NADPH), which is used as a reducing agent in several biosynthetic pathways and is also
important for protection against oxidative damage. (2) synthesis of ribose 5-phosphate, which is
required for nucleotide and nucleic acid synthesis [25]. Considering the tissue distribution in humans,
the expression levels of PPP enzymes vary widely from tissue to tissue. Relatively high levels are found
in the liver, the adrenal cortex, the testicles and ovaries, the thyroid, and the blood in the red blood cells.
In all of these, a continuous supply of NADPH is required to support reductive biosynthesis and/or to
counteract the effects of oxygen free radicals or reactive oxygen species (ROS). Contrasting action on
the effects of ROS is particularly important in cells such as red blood cells, which are directly exposed to
oxygen [26]. In erythrocytes, the main function of PPP appears to be the maintenance of glutathione in
the reduced state and preservation of cell membrane structure [27]. NADPH is used for the reduction
of oxidized glutathione (GSSG) to reduced glutathione (GSH). GSH is important for the detoxification
of ROS and converts reactive hydrogen peroxide into H2O. Moreover, high levels of enzymes of this
metabolic pathway are also present in rapidly dividing cells such as those of the embryo in the early
stages of development. The alteration of this pathway in CVS samples with β-thalassemia suggests
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both a demand of high quantities of ribose 5-phosphate for nucleotide synthesis (typical of embryonic
development) and increased oxidative stress with the need to respond with anti-oxidative mechanisms
such as NADPH production and PPP activation (particularly considering the comparison with the
control group). Oxidative stress is an important mechanism in the progression of β-thalassemia,
and alterations in this pathway are not unexpected. Oxidative stress in patients with β-thalassemia
is mainly caused by peroxidative injury due to secondary iron overload. Additionally, production
of free radicals by iron overload plays an important role in the pathogenesis of β-thalassemia [28].
Moreover, the oxidation of hemoglobin alpha leads to the formation of hemicromes. Hemicromes bind
to and modify many components of the red blood cell membrane precipitating and causing the
disintegration of the heme, resulting in the release of compounds containing toxic iron. Free iron
catalyzes the formation of active oxygen compounds [29].
In patients with β-thalassemia, antioxidant molecules and enzymes are significantly decreased.
The continuous production of ROS overwhelms the antioxidant machinery very rapidly [30].
Oxidant damage to thalassemic erythroid precursors can cause their accelerated apoptosis
and ineffective erythropoiesis [31]. One of the best described effects of ROS on cells is the
oxidative modification of fatty acids within membrane phospholipids, i.e., lipoperoxidation [32].
Oxidative modification of membrane phospholipids can result in the alteration of membrane fluidity,
protein structure, and cell signaling. Oxidative stress and peroxidation of membrane phospholipids
have been shown to enhance phospholipases A2 (PLA2) activity [33], which can give rise to a number
of biologically active mediators such as ARA, a polyunsaturated fatty acid present in the phospholipids
of membranes of the body’s cells. The major action of ARA is the promotion of acute inflammatory
response, characterized by the production of proinflammatory mediators [34] such as PGE2 and
PGI2. The study of β-thalassemia is not simple, especially from a metabolic point of view and
in an early stage such as embryonic life. The interpretation of the metabolic changes in fetuses
affected by β-thalassemia requires a strong effort considering both the lack of information in scientific
literature and the heterogeneity of this disease; therefore, our findings can only provide a hypothesis.
Fetal hemoglobin is formed by one alpha and two gamma subunits. These fetuses have the gene
mutation for the beta globin, which is the only variable that differentiates them from the control group
in our analysis. We can hypothesize that the presence of oxidative stress could be correlated to the
presence of the mutation even if the defective beta globin has not yet been expressed.
5. Conclusions
In this study, an increase in the metabolites involved in energetic pathways, such as the pentose
phosphate pathway, directly linked to the production of antioxidant species, was observed in
chorionic villi from fetuses with homozygous β-thalassemia, suggesting an oxidative stress status.
Oxidative stress negatively impacts several biological functions of β-thalassemia and can play an
important role in its pathogenesis. A better understanding of the primary biological events of this
condition may provide new avenues for the management of this serious condition.
This was a preliminary study that showed how metabolic alterations could be present in early
pregnancy in placental tissue of fetuses affected byβ-thalassemia. Due to the novelty of these results and
considering the lack of studies of metabolism changes in β-thalassemia patients, further investigation
is necessary.
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